Viral Inactivation Market Overview, Key Trends, and Insights on Leading Companies

The viral inactivation industry is poised for substantial expansion over the coming years as demand intensifies for processes that ensure the safety of biologics and other therapeutic products. Advancements in technology and growing investments in bioprocessing infrastructure are setting the stage for a transformative period in this market. Here's an in-depth exploration of its expected growth, key players, emerging trends, and market segmentation.

Forecasted Growth and Market Size of the Viral Inactivation Industry
The viral inactivation market is projected to experience significant growth, reaching a valuation of $9.17 billion by 2030. This represents a strong compound annual growth rate (CAGR) of 10.9%. The anticipated surge is driven by multiple factors including rising demand for biologics and biosimilars, increased investments in state-of-the-art bioprocessing facilities, a growing emphasis on continuous manufacturing, wider adoption of automated quality control mechanisms, and the scaling of vaccine production pipelines. Key trends shaping this market include the growing use of automated viral inactivation technologies, heightened focus on validated virus safety protocols, expansion of continuous flow inactivation methods, broader implementation of single-use bioprocessing tools, and stronger attention to reproducibility and regulatory compliance.

Download a free report of the viral inactivation market report:
https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Drivers Accelerating Viral Inactivation Market Expansion
The viral inactivation market is growing rapidly due to the increasing global demand for biologic drugs and biosimilars, which require stringent viral safety protocols to ensure patient safety. This demand is fueling the need for innovative viral inactivation methods that can be integrated into advanced bioprocessing workflows.
Additionally, the expansion of vaccine manufacturing pipelines worldwide has created a pressing need for reliable viral clearance technologies. Regulatory agencies are placing greater emphasis on virus safety, which is encouraging manufacturers to adopt validated and automated viral inactivation systems to meet compliance standards effectively.

Leading Companies Making an Impact in Viral Inactivation
Several prominent companies are shaping the competitive landscape of the viral inactivation market. These include Merck & Co. Inc., Sartorius AG, Texcell SA, SGS SA, Charles River Laboratories Inc., Clean Cells SAS, Rad Source Technologies, WuXi AppTec, Sigma-Aldrich Co. LLC, Thermo Fisher Scientific Inc., Macopharma, Cerus Corporation, TERUMO BCT INC., Pall Corporation, Eurofins Scientific, Cytiva, Viral Inactivated Plasma Systems SA, Eurofins Scientific SE, Lonza Group AG, Avantor Inc., Bio-Rad Laboratories Inc., and F. Hoffmann-La Roche AG.
In a notable development in November 2025, Croda International Plc, a UK-based specialty ingredients firm, formed a strategic partnership with Germany's Amino GmbH. This collaboration aims to enhance global access to high-purity amino acids for pharmaceutical formulations and biomanufacturing. By combining Croda's specialty ingredients expertise with Amino's precision manufacturing capabilities, the partnership focuses on accelerating therapy development, ensuring consistent regulatory-grade raw material supply, improving sustainability, and boosting manufacturing efficiency.

View the full viral inactivation market report:
https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Innovations Shaping Viral Inactivation Technologies
Market leaders are increasingly integrating advanced viral clearance technologies designed to improve the safety of biologics, streamline regulatory compliance, and enhance process efficiency. These technologies employ chemical, physical, or filtration-based methods to inactivate viruses and provide log-reduction validation as well as regulatory-compliant safety assurance.
For example, in May 2025, Northway Biotech, a contract development and manufacturing organization (CDMO) headquartered in Lithuania, launched Full-Service Viral Clearance Studies (VCS). This comprehensive viral clearance solution accelerates safety validation for protein biologics and gene therapies by utilizing multiple identical BSL-2 labs for high-throughput workflows, BSL-3 testing capabilities, and delivers full regulatory-compliant viral clearance results within 10 weeks-a speed significantly faster than typical industry timelines. This innovation supports faster development cycles, better cost management, and improved regulatory readiness for biopharma clients.

Detailed Segmentation of the Viral Inactivation Market
The viral inactivation market is organized into key segments based on product, method, application, and end user.
1) Product categories include Kits and Reagents, Systems, and Services.
2) Methods comprise the Solvent Detergent Method, pH Adjustment Method, Pasteurization, and Other Methods.
3) Applications cover Vaccines and Therapeutics, Tissues and Tissue Products, Blood and Blood Products, and other uses.
4) End users include Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Blood Banks, Hospitals, Academic Research Institutes, and others.

Further subcategories under these major groups include:
- Kits and Reagents such as Viral Inactivation Kits, PCR Reagents, and Antibodies and Enzymes.
- Systems like Automated Viral Inactivation Systems, Batch Viral Inactivation Systems, and Continuous Flow Systems.
- Services including Viral Testing Services, Validation Services, and Consulting Services.

This segmentation provides a comprehensive understanding of the market's structure and the various technologies and applications that are driving its ongoing growth.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.